The RB@PVA matrix demonstrated cytotoxicity against PC-3 prostate cancer cells, with an IC50 value of 1.19 μM compared to 2.49 μM for free RB, indicating enhanced efficacy. The gene discussed is RB1; the disease is prostate carcinoma.